Stem-Cell Advance Promises Drug Development Success

By Richard Levick, London Press Service

SCIENTISTS have developed unique technology to grow stem cells and other tissue in the laboratory in conditions similar to the way they grow in the human body.

The technology - developed and patented by scientists at Durham University, England, and its spin-out company ReInnervate - is a plastic scaffold that allows cells to be grown in a more realistic three-dimensional (3D) form compared with the traditional flat surface of a petri dish.

Evidence gathered by the research team shows that the technology is a low-cost and straightforward way of cultivating cells in 3D. Using it could lead to more successful drug development programmes and a reduction in tests on animals.

A study proving the effectiveness of the scaffold, funded by ReInnervate and the Engineering & Physical Sciences Research Council (EPSRC), has been published in the Journal of Anatomy.

A large proportion of drugs fail at the testing stage, costing the industry millions in research and development costs and failed drugs trials every year.

Today, most drugs in development are first tested on cells grown in two dimensions (2D) in standard laboratory equipment such as petri dishes or flasks - but cells in the human body form tissues and grow in more complex, 3D ways.

The new study tested the toxic effect of a cancer drug called methotrexate (MTX) on liver cells grown in three and two dimensions. Liver cells are frequently used in the drug development industry to test the toxicity of drugs; MTX is known to cause liver damage at high doses.

Tests showed that the structure and properties of the cells grown using the 3D scaffold were most similar to liver cells found in the human body, compared with the 2D cells that appeared "disorganised" when viewed under the microscope.

When subjected to doses of MTX, cells grown in 2D died at very low concentrations, whereas 3D cells grown using the scaffold were far more robust and more accurately reflected the behaviour of cells in the human body when subjected to similar doses of the drug.

Dr Stefan Przyborski, a researcher with Durham University and chief scientific officer of ReInnervate, has tested 10 tissue types on the scaffold - including bone, liver, fat and stem cells from bone marrow - and is marketing the product for commercial use.

The scaffold is made of highly porous polystyrene, is about the size of a thumbnail and resembles a thin white disc. It has a structure resembling that of a sponge and is riddled with tiny holes that scientists are able to populate with cells that are then cultivated under laboratory conditions.

The technology has the potential to be used to grow human stem cells for drug development. Their use may reduce the need for the tests on animals that are usually the next step before progressing to clinical trials in humans. Another use of the scaffold involves growing skin cells that are being used by the cosmetics industry to test its products.

Dr Przyborski said: "Our results suggest that testing drugs on liver cells using our 3D culture system may be more likely to reflect true physiological responses to toxic substances. Because the 3D cells are cultivated under more realistic conditions, it means that they function more like real tissues.

"Scientists are therefore able to gain a more accurate idea of how a drug will behave in the human body, knowledge which can contribute to improving the efficiency of drug discovery, reducing drug development costs, and may help reduce the number of animals in research.

There are other ways to growing cells in 3D in the laboratory. However, these approaches are restricted by their variability, complexity, expense and they are not easily adapted to routine use in high-throughput screening studies," he added.

"Our technology is essentially a well engineered piece of plastic that provides a suitable environment for cells to grow more naturally in a 3D configuration. Our product is available off-the-shelf, it is easy to use in routine applications, it is highly adaptable to different tests, it is inert and it is cheap and easy to produce and manufacture," said Dr Przyborski.

Dr Przyborski and colleagues at Durham University play a key role in the North-east England Stem Cell Institute (NESCI), described as a unique interdisciplinary collaboration to convert stem-cell research and technologies into cost-effective, ethically robust 21st-century health solutions to ameliorate degenerative diseases, the effects of ageing and serious injury.

Contact:

Durham University Media Relations
University Office, Old Elvet, Durham, United Kingdom, DH1 3HP
Phone: +44 191 334 6075
E-mail: media.relations@durham.ac.uk
Web: www.dur.ac.uk/news OR www.reinnervate.com